Immunomodulatory Mechanisms in Multiple Sclerosis Therapy

Multiple sclerosis (MS) is an immune‐mediated disorder of the central nervous system characterised by autoreactive lymphocytes breaching the blood–brain barrier and driving inflammation, demyelination and neurodegeneration. Therapeutic immunomodulation aims to recalibrate the balance between pathogenic and regulatory immune pathways. Approved strategies include small‐molecule modulators of sphingosine‐1‐phosphate receptors that sequester lymphocytes in lymphoid organs, monoclonal antibodies that deplete or prevent trafficking of specific lymphocyte subsets, and peptide‐based agents that skew T helper cell phenotypes towards regulatory profiles. These interventions reduce lymphocyte egress, inhibit pro-inflammatory cytokine cascades and promote expansion of regulatory T and B cell populations. Emerging evidence also highlights secondary neuroprotective actions, such as mitigation of endoplasmic reticulum stress and preservation of mitochondrial integrity in affected neural tissues. Advances in transcriptomic and immunophenotyping techniques have elucidated treatment‐induced molecular signatures and identified potential biomarkers of response, informing personalised therapeutic selection and paving the way for next‐generation immunomodulatory approaches.

Research from Nature Portfolio

In an experimental autoimmune encephalomyelitis model, treatment with a peptide‐based immunomodulator restored mitochondrial structure and alleviated endoplasmic reticulum stress in spinal cord lesions, underscoring a link between peripheral immune modulation and direct neuroprotective effects. Separately, high‐density transcriptome profiling of circulating CD4+ lymphocytes before and after sphingosine-1-phosphate receptor modulation revealed a distinct gene‐expression signature marked by downregulation of lymph node egress molecules and upregulation of regulatory surface markers. These studies collectively demonstrate that immunomodulatory therapies not only restrain pathogenic cell trafficking but also reprogramme surviving lymphocytes toward antiinflammatory phenotypes and may confer resilience to neural elements.

Immunomodulatory Mechanisms in Multiple Sclerosis Therapy publication trend

The graph below shows the total number of articles in immunomodulatory mechanisms in multiple sclerosis therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Experimental autoimmune encephalomyelitis (EAE): An animal model of MS induced by immunisation with myelin antigens, used to study inflammatory demyelination and test immunotherapies.

Sphingosine-1-phosphate receptor (S1PR): A G-protein-coupled receptor on lymphocytes; its modulation prevents lymphocyte egress from lymphoid tissues.

Regulatory T cell (Treg): A subset of CD4+ T lymphocytes that suppresses immune responses and maintains self-tolerance.

Endoplasmic reticulum stress: A cellular condition arising from accumulation of misfolded proteins in the endoplasmic reticulum, contributing to neuronal injury.

Transcriptomics: The comprehensive analysis of RNA transcripts to profile gene‐expression changes under different conditions or treatments.

References

1. Immunological Aspects of Approved MS Therapeutics. Frontiers in Immunology (2019).
2. Immunomodulatory therapy with glatiramer acetate reduces endoplasmic reticulum stress and mitochondrial dysfunction in experimental autoimmune encephalomyelitis. Scientific Reports (2023).
3. Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis. Scientific Reports (2017).
4. Response to Fingolimod in Multiple Sclerosis Patients Is Associated with a Differential Transcriptomic Regulation. International Journal of Molecular Sciences (2024).
5. Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications. Journal of Neurology (2024).